Patents by Inventor Mikael Sunnåker

Mikael Sunnåker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES
    Publication number: 20240358698
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Application
    Filed: July 5, 2024
    Publication date: October 31, 2024
    Inventors: Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
  • Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
    Patent number: 12121517
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: October 22, 2024
    Assignee: ASTRAZENECA AB
    Inventors: Peter Greasley, Christine Ahlström, Stanko Skrtic, Robert Menzies, Anne-Kristina Mercier, Mikael Sunnåker
  • COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF PROTEINURIA CHRONIC KIDNEY DISEASE
    Publication number: 20240307383
    Abstract: Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
    Type: Application
    Filed: February 7, 2024
    Publication date: September 19, 2024
    Inventors: Philip Ambery, Peter Greasley, Anne-Kristina Mercier, Mikael Sunnåker
  • METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS
    Publication number: 20240218064
    Abstract: The present invention relates to methods for treating vascular inflammation, atherosclerosis and related disorders in a subject using a lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) binding protein, such as an anti-LOX-1 antibody or a LOX-1 binding fragment thereof. Also disclosed are dosage regimens for use in treating LOX-1 related disorders.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Inventors: Anna COLLÉN, Richard Thomas GEORGE, Jr., Emily L. ONGSTAD, Andrea Lynn VAVERE, Angelica QUARTINO, Vincent DUBOIS, Mikael SUNNÅKER
  • COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES
    Publication number: 20230364077
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Application
    Filed: June 23, 2023
    Publication date: November 16, 2023
    Inventors: Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
  • Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
    Patent number: 11730735
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: August 22, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Peter Greasley, Christine Ahlström, Stanko Skrtic, Robert Menzies, Anne-Kristina Mercier, Mikael Sunnåker